LACTOLOGY FOUNDATION

Contact laxatives in combination (ATC A06AB20) are stimulant laxative preparations that combine one or more contact-acting agents with other laxative classes or excipients to enhance stool softening and colonic motility in the management of constipation.atcddd.fhi+1

ATC and pharmacological class

ATC code A06AB20 belongs to the subgroup A06AB “contact laxatives” within A06 “drugs for constipation” in the WHO Anatomical Therapeutic Chemical Classification System.wikipedia
Contact laxatives (stimulant laxatives) act primarily on the intestinal mucosa to increase fluid secretion and stimulate smooth muscle contraction, thereby accelerating colonic transit.medpedia.framar+1
The A06AB20 entry specifically denotes combinations of contact laxatives, often together with osmotically acting laxatives or other agents, rather than single active substances.atccode+1

Mechanism of action and pharmacodynamics

Drugs in A06AB20 share the pharmacodynamic profile of stimulant laxatives: they irritate or activate sensory nerve endings in the intestinal wall, increasing peristaltic activity and promoting evacuation several hours after administration.naver+1
Many modern combinations include diphenylmethane derivatives (such as bisacodyl or sodium picosulfate) whose active metabolite BHPM acts locally in the colon with minimal systemic absorption, enhancing secretion and motility without central nervous system effects or established dependence.efsm+1
When combined with osmotic laxatives, the contact component accelerates motility while the osmotic agent draws water into the lumen, resulting in softer stools and more effective clearance of colonic contents.atcddd.fhi+1

Therapeutic use and dosing principles

A06AB20 combinations are indicated for short‑term relief of constipation and for bowel preparation when rapid or complete evacuation of the colon is required (e.g. before endoscopic or radiological procedures).drugbank+1
Clinical guidelines for adult constipation typically recommend bulk-forming and osmotic laxatives as first-line options, with stimulant or contact laxatives—alone or in combination—added when stools are soft but difficult to pass or when more rapid action is needed.breastfeedingnetwork+1
Treatment should start with the lowest effective dose, titrated to achieve one to two soft, formed stools per day, and stimulant combinations should be reserved for occasional use to avoid unnecessary reliance on their action.primarycare.northeastlondon.icb+1

Safety profile in general population

Because many contact laxatives act locally in the gut and are poorly absorbed, systemic adverse effects are limited; typical reactions include abdominal cramping, urgency, and transient diarrhea.sps+1
Long‑term data for some components, particularly bisacodyl, suggest absence of true habituation or structural colonic damage when used appropriately, although routine chronic use of stimulant combinations is discouraged in favor of stepwise management strategies.efsm+1
Certain older agents in the contact laxative class, such as phenolphthalein, have largely been withdrawn due to safety concerns including suspected carcinogenicity, underscoring the need to distinguish modern A06AB20 combinations from historical stimulants.e-lactancia+1

Use during pregnancy and lactation (toxico‑lactological aspects)

Stimulant/contact laxatives used in modern combinations are generally considered low risk in pregnancy when occasional use is necessary, and there is no consistent evidence over several decades of teratogenic or embryo‑toxic effects for widely used agents such as bisacodyl.efsm
Most laxatives, including stimulant agents, are either not absorbed or minimally absorbed from the gastrointestinal tract, leading to negligible transfer into breast milk and allowing their use during breastfeeding with appropriate clinical judgment.sps+1
Specialized teratology and lactation databases (e.g. Embryotox) conclude that breastfeeding is compatible without restriction during bisacodyl therapy, and clinical breastfeeding resources report no proven adverse effects in infants exposed to bisacodyl or sodium picosulfate, although occasional loose stools cannot be excluded.breastfeedingnetwork+1

Place in therapy in breastfeeding women

In breastfeeding patients with constipation, evidence‑based recommendations usually favor bulk-forming or osmotic laxatives as first‑line choices, given their predictable safety and minimal systemic absorption.sps+1
Contact laxative combinations (A06AB20) can be considered when first‑line agents are insufficient, particularly for short‑term use or procedural bowel preparation, with attention to maternal factors such as underlying disease, concomitant medications, and risk of dehydration.primarycare.northeastlondon.icb+1
When A06AB20 regimens are used in lactating women, monitoring the infant’s stool pattern is prudent, but current data support their compatibility with breastfeeding when used at standard doses under medical supervision.breastfeedingnetwork+1